migalastat

Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent. As the earnings season kicks into high gear and amid several other catalysts, August is likely to be an action-packed...

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) soared higher by more than 25 percent on Tuesday in reaction to the company's announcement that there is now a clear path to approval for its migalastat NDA therapy. Amicus suffered a major setback for its therapy in November, 2016 when the U.S....

Amicus Therapeutics, Inc. (NASDAQ: FOLD) announced the path forward for U.S. regulatory approval for migalastat, including an additional trial in Fabry disease, focused on gastrointestinal (GI) symptoms. JPMorgan’s Anupama Rama maintains an Overweight rating on the company, while lowering the...

Bank of America's Peter Stapor initiated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ: FOLD) with a price target of $10.00. The leading drug in the company's portfolio is migalastat (Galafold) for a rare disease (Fabry disease), which results in enzyme deficiency and can lead to organ failure...